need for some means of differential diagnosis of pleural effusion to distinguish between benign and malignant, to achieve better prognosis. Cytological examination can distinguish the nature of pleural effusion as a basis for diagnosis, but unfortunately, the positive rate is only between 11% and 78%. 5 Thoracoscopy can improve the diagnostic efficacy, that the sensitivity can reach about 90%. 6 However, this invasive inspection due to cost, risk, and technical requirements and other factors cannot be widely used in clinical practice.
Nowadays, the conventional test markers of pleural effusion including pleural fluid adenosine deaminase (pADA), pleural fluid lactate dehydrogenase (pLDH), pleural fluid glucose (pGLU), pleural fluid ferritin (pFER), pleural fluid carbohydrate antigen 19-9 (pCA199), pleural fluid carbohydrate antigen 125 (pCA125), pleural effusion white cell count (pWBC), pleural effusion red cell count (pRBC), but those markers all have a low sensitivity and specificity.
In recent years, many researchers are looking for reliable biomarkers that can differentiate MPE.
Midkine (MK) is a heparin-binding growth factor, has angiogenic activity and can signal through ALK receptors, 7, 8 and can prevent cell apoptosis and enhance cell viability and migration. 9 In recent years, it has been shown to be highly expressed in most cancers and play a central role in carcinogenesis, and is closely related to its aggressiveness. 9, 10 Thus, MK has become a new marker that is expected to be used in the diagnosis and prognosis of multiple cancers. 11,12 X Xia's study showed that MK in the serum and urine from NSCLC patients had a high expression, can be used to determine the prognosis.
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In this study, we aim to explore the clinical role of MK joint with other routine markers in the differential diag of carbohydrate antigen 19nosis of malignant pleural effusion caused by NSCLC and the possibility of impact on tumor metastasis, to guide proper treatment and achieve a better prognosis. 
| MATERIAL S AND ME THODS

| RE SULTS
All of the parameters were not normally distributed as determined by the Shapiro-Wilk test. The results were further analyzed by the Mann-Whitney U test. The pMK, pCA125, pMK + pCA125 level and pMK + pCA125 + pADA level in the MPE were significantly higher than the BPE group (Mann-Whitney U = 1362.000, 1126.000, 929.000, 719.000 P = .003, .000, .000, .000). The pADA level in the BPE was significantly higher than the MPE group (Mann-Whitney U = 1349.000, P = .003). The pLDH, pGLU, pWBC, pRBC, pFER, pCA199 in the MPE showed no significant difference when compared with the BPE group (see Figure 1 and Table 1 ). Figure 2 and Table 2 ).
The relationship between expression level of MK in clinical variables was summarized in Table 3 . No statistically significant difference was seen between level of MK and age (P = .981), gender (P = .175), cigarette smoking status (P = .094), the histological type (P = .714), the status of lymph node metastasis (P = .113) and distant metastasis (P = .564).
| D ISCUSS I ON
In China, cancer (especially lung cancer) and tuberculosis are the main cause of pleural effusion. However, the prognosis and treatment approaches are evidently different, and it is extremely important for the differential diagnosis of BPE and MPE. The routine test item such as histopathology and cytology was the gold-standard methods, but an important limitation was those methods probably lacked of sensitivity. So, the diagnosis of BPE and MPE is still a clinical problem. In searching for new biological marker, we examined the expression of MK and other routine markers in pleural effusions.
F I G U R E 1
Comparison of the parameters in pleural effusion from both groups. A, The pMK level in the malignant pleural effusion (MPE) group was significantly higher than which in the benign pleural effusion (BPE) group. The pADA level in the BPE group was obviously higher than witch in the MPE group. B, The pleural fluid CA125 level in MPE was markedly higher than that in the BPE group. pADA, pleural fluid adenosine deaminase; pMK, pleural fluid Midkine F I G U R E 2 ROC curve of parameters for the diagnosis of MPE. At the cutoff value = 0.47, the sensitivity and specificity of joint detection of pMK, pADA, and pCA125 were 82.54%, 74.19% for the diagnosis of MPE, and the AUC (0.816) was the highest among all the other markers tested. AUC, area under the ROC curve; MPE, malignant pleural effusions; pADA, pleural fluid adenosine deaminase; pMK, pleural fluid Midkine Midkine, a growth factor, at the beginning was identified as the product of a retinoic acid responsive gene expressed during embryogenesis. MK is involved in the proliferation, invasion, and metastasis of tumor cells in cancer and has obvious regulation effect on tumor neovascularization. 13, 14 In a variety of cancer, the expression was higher than normal tissue. 9, 10 Recent years, enzyme immunoassays have been developed to detect this protein, and some reports were
shown that an increase in the serum and urinary in patients with many kinds of cancer.
10,11,15
Cancer Antigen-125 (CA125) is a glycoprotein which is expressed on the surfaces of ovarian cancer cells, which has been widely used as a primary screening index of human ovarian cancer.
Subsequently, research shows that human mesothelial cells were also demonstrated to secrete CA125. However, the specificity of CA125 in the diagnosis of cancers remains controversial. Research by Li, X reported that CA125 was expressed in lung cancer tissues, with the expression level closely related to the degree of differentiation of the tumor.
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TA B L E 2 The AUC, cutoff value, sensitivity, and specificity of parameters for the diagnosis of MPE The size of AUC shows that the veracity of diagnostic tests. It has a lower diagnostic value when AUC is from 0.5 to 0.7 and has the higher diagnostic value when AUC > 0.8. In our study we found that at the cutoff 0.47, the sensitivity and specificity of the joint detection of pMK, pCA125 and pADA were 82.54% and 74.19% for the diagnosis of MPE and the AUC 0.816, giving it a significantly higher diagnostic value for MPE than the other studies indicators. The results of joint detection of pMK, pCA125, and pADA indicated that diagnostic performance was significantly higher than that of pMK or the joint detection of pMK and pCA125.
In our study, the results revealed that there was no evident relationship between the expression of MK in NSCLC-associated malignant pleural effusion and the clinical variables as age, gender, cigarette smoking status, the histological type, the status of lymph node metastasis or distant metastasis.
In summary, the joint detection of pMK, pCA125, and pADA has a high diagnostic efficacy for differential diagnosis of NSCLCassociated MPE, and hence, it is an important marker to determine the nature of pleural effusion, which can play a certain role in guiding suitable clinical treatment and the prognosis evaluation. Thus, joint detection of pMK, pCA125, and pADA has better diagnostic performance than pMK or the joint detection of pMK and pCA125, and all the 3 markers were simple and noninvasive, could be used in routine screening programs. Our study provides a new idea of noninvasive examination for the clinical diagnosis of NSCLC.
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